Blinatumomab Conundrum in Low-Risk Relapsed B-Cell ALL

Area of Science:

• Pediatric Oncology
• Hematology
• Clinical Trials

Background:

• The Children's Oncology Group (COG) AALL1331 trial evaluated blinatumomab in relapsed acute lymphoblastic leukemia (ALL).
• Blinatumomab improved survival and reduced toxicity in high-/intermediate-risk relapsed ALL before hematopoietic stem-cell transplant (HSCT).
• In low-risk ALL, blinatumomab did not improve survival, though it showed benefits for bone marrow disease with extramedullary involvement.

Approach:

• This case report addresses challenges in managing late isolated central nervous system (CNS) B-cell ALL relapse.
• Challenges include defining low-risk criteria, reducing treatment burden, and optimizing cranial irradiation timing and approach.
• A modified chemotherapy backbone with cranial radiotherapy is recommended for late isolated CNS relapse, differing from AALL1331's approach.

Key Points:

• Blinatumomab demonstrated efficacy in high-risk relapsed ALL but not in all low-risk scenarios.
• Isolated extramedullary relapse did not benefit from blinatumomab.
• Isolated CNS relapse showed poor survival, indicating blinatumomab's inadequacy for CNS disease control.

Conclusions:

• Late isolated CNS relapse in ALL presents unique management challenges.
• Current blinatumomab-based regimens may be insufficient for CNS disease.
• Future research should explore novel therapies like CAR T-cells for improved CNS penetration and reduced treatment intensity.